Who are Oxycodone, fentanyl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fentanyl-Morphine, Ketamine + methadone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxycodone-fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Oxycodone, fentanyl — Competitive Intelligence Brief

Oxycodone, fentanyl (Oxycodone, fentanyl) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist combination. Area: Pain Management.

marketed Opioid agonist combination Mu-opioid receptor (OPRM1) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Oxycodone, fentanyl (Oxycodone, fentanyl) — Danish Pain Research Center. This is a combination of two opioid agonists that bind to mu-opioid receptors in the central nervous system to produce analgesia and pain relief.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Oxycodone, fentanyl TARGET	Oxycodone, fentanyl	Danish Pain Research Center	marketed	Opioid agonist combination	Mu-opioid receptor (OPRM1)
Fentanyl-Morphine	Fentanyl-Morphine	Seoul National University Hospital	marketed	Opioid agonist combination	Mu-opioid receptor (OPRM1)
Ketamine + methadone	Ketamine + methadone	Cedars-Sinai Medical Center	marketed	NMDA receptor antagonist + synthetic opioid agonist combination	NMDA receptor (ketamine); mu opioid receptor (methadone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist combination class)

Danish Pain Research Center · 1 drug in this class
Seoul National University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oxycodone, fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/oxycodone-fentanyl. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab